Loading
Cheap, essential chemotherapy drugs such as cisplatin keep running short because there is little profit in making them. A publicly-backed non-profit manufacturer would guarantee supply at a fair price.
Extend the Civica Rx and California CalRx model to a portfolio of essential oncology generics that repeatedly fall into shortage (cisplatin, carboplatin, methotrexate, fluorouracil, vincristine, etoposide, BCG): a non-profit manufacturer or contracted network with public capital, long-term purchase agreements from hospital systems and national payers, redundant production sites, and transparent cost-plus pricing. Where the public option also supplies low- and middle-income countries through pooled procurement, it addresses global access at the same time. The problem is not scientific; it is a market that rewards exit from low-margin sterile injectables.
Shares Prices and value, Most of the world has almost no cancer care, Paclitaxel / nab-paclitaxel, Platinum agents.
Shares Prices and value, Most of the world has almost no cancer care, Platinum agents, Carboplatin.
Shares Prices and value, Most of the world has almost no cancer care, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Incentives reward me-too drugs and marginal gains, Prices and value, Most of the world has almost no cancer care.
Shares Prices and value, Cytotoxic chemotherapy.
Shares Prices and value, Most of the world has almost no cancer care.
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Hospital-based CAR-T manufacturing at cost through a public network, Incentives reward me-too drugs and marginal gains, Prices and value.